When a brand-name drug to help prevent premature births was approved last year, its $1,500-a-dose-price alarmed state and private sector insurance officials. Many restricted use of the FDA-approved Makena in favor of $20- to $40-a-dose versions that had been made for years by pharmacies, saying that would give more women access to the treatment.
Insurance Policies Favoring Compounded Drugs For High-Risk Pregnancies Draw Scrutiny
In this photo made available, Oct. 9, 2012, by the Minnesota Department of Health shows shows vials of the injectable steroid product made by New England Compounding Center implicated in a fungal meningitis outbreak that were being shipped to the CDC from Minneapolis. (AP Photo/Minnesota Department of Health, File) When a brand-name drug to help […]